Avian Influenza News and Research

RSS

Avian influenza is an infection caused by avian (bird) influenza (flu) viruses. These influenza viruses occur naturally among birds. Wild birds worldwide carry the viruses in their intestines, but usually do not get sick from them. However, avian influenza is very contagious among birds and can make some domesticated birds, including chickens, ducks, and turkeys, very sick and kill them.

Former CDC head to lead Merck's vaccine division

The pharmaceutical company Merck on Monday named former CDC head Julie Gerberding as president of the company's vaccine division, Reuters reports. "Gerberding, who led the CDC from 2002 to 2009 and stepped down when President Barack Obama took office, will head up the company's $5 billion global vaccine business that includes shots to prevent chickenpox, cervical cancer and pneumonia," the news service reports.

22 Dec 2009

Positive interim results from Medicago's H5N1 vaccine Phase I human clinical trial

Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase I human clinical trial with its H5N1 Avian Influenza vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

21 Dec 2009

EPA approves BASF's Aseptrol S10 - Tab for H1N1 sanitization operations

BASF today announced that the Environmental Protection Agency (EPA) has approved the use of Aseptrol® S10 - Tab in H1N1 sanitization operations in institutional and industrial facilities, such as, schools, hospitals, government buildings, retail and restaurants, and recreational facilities. Aseptrol S10 - Tab is based on Chlorine dioxide (CIO2) release technology.

17 Dec 2009

Researchers identify new biological pathway of H1N1 transmission to human population

A new biological pathway by which the H1N1 flu virus can make the jump from swine to humans has been discovered by researchers with the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) and the University of California, Berkeley. Early test results indicate that a heretofore unknown mutation in one of the H1N1 genes may have played an important role in transmitting the virus into humans.

11 Dec 2009

Computer search algorithms identify FDA-approved drugs that could be the basis for new medicines

A massive, data-crunching computer search program that matches fragments of potential drug molecules to the known shapes of viral surface proteins has identified several FDA-approved drugs that could be the basis for new medicines -- if emerging viruses such as the H5N1(avian flu) or H1N1/09 (swine flu) develop resistance to current antiviral therapies -- according to a presentation at the American Society for Cell Biology (ASCB) 49th Annual Meeting, Dec. 5-9, 2009 in San Diego.

7 Dec 2009

Tripep completes phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that its partner Tripep AB of Sweden has completed its phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine delivered using Inovio’s electroporation technology.

30 Nov 2009

Lethality of H1N1 virus has dropped from its peak of 3.7, shows new data

Biotech firm Replikins Ltd., which has analyzed the H1N1 virus' genomic data from the 1918 pandemic through the prediction, outbreak, and progress of the current H1N1 pandemic, today issued its latest biochemical analysis of the virus.

25 Nov 2009

Inovio Biomedical announces positive test results of its consensus influenza vaccines

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2, and H5N1 influenza vaccine candidates achieved protective antibody responses against several different influenza sub-types and strains in ferrets.

20 Nov 2009

DxNA announces successfull evaluation of its GeneSTAT PCR system

DxNA, a molecular diagnostics company headquartered in St. George, Utah, announced today that the DxNA GeneSTAT PCR system has successfully completed evaluation studies under the direction of a California laboratory supported by the Joint FAO/IAEA Programme in Food and Agriculture.

19 Nov 2009

Why avian flu virus has not caused a pandemic?

Bird flu viruses would have to make at least two simultaneous genetic mutations before they could be transmitted readily from human to human, according to research published today in PLoS ONE.

19 Nov 2009

SynCon Chikungunya virus DNA vaccine induces protective neutralizing antibody responses in animal model

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company's SynCon™ Chikungunya virus DNA vaccine induced protective neutralizing antibody responses in a preclinical non-human primate model.

18 Nov 2009

Molecular makeup of current H1N1 flu strain strikingly different from previous H1N1 strains

As the number of deaths related to the pandemic H1N1 virus, commonly known as "swine flu," continues to rise, researchers have been scrambling to decipher its inner workings and explain why the incidence is lower than expected in older adults.

17 Nov 2009

New Web-based application for tracking the H1N1 flu virus across the globe

New methods of studying avian influenza strains and visually mapping their movement around the world will help scientists more quickly learn the behavior of the pandemic H1N1 flu virus, Ohio State University researchers say.

17 Nov 2009

Scientists find major genetic differences between the pandemic H1N1 strain and seasonal strains

17 Nov 2009

Inovio Biomedical reports financial results for the three and nine months ended September 30, 2009

Inovio Biomedical Corporation today reported financial results for the three and nine months ended September 30, 2009.

16 Nov 2009

Pregnant women tolerate the 2009 H1N1 flu vaccine, mount strong immune response

Healthy pregnant women mount a robust immune response following just one dose of 2009 H1N1 influenza vaccine, according to initial results from an ongoing clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

3 Nov 2009

RESPOND program to improve global perspective on emerging diseases

Experts from the University of Minnesota will soon be on the frontlines working to help developing countries better respond to emerging animal diseases that pose a threat to human health.

31 Oct 2009

Tufts University receives $185M grant as part of the USAID Emerging Pandemic Threats program

Tufts University has been tapped by the United States Agency for International Development (USAID) as part of a multidisciplinary team that will receive a grant of up to $185-million to create better synergies among veterinarians, doctors, and public health officials in responding to emerging infectious diseases.

31 Oct 2009

Five-year program aimed at preventing future pandemic diseases awarded to DAI

DAI has been awarded a five-year program aimed at preventing future pandemics such as HIV/AIDS and H1N1.

30 Oct 2009

NIH awards contract to LRRI for anthrax research

Lovelace Respiratory Research Institute (LRRI) was recently awarded a contract to continue research due to the potential for bioterrorist attacks involving Bacillus anthracis, the causative agent of anthrax, by the National Institutes of Allergy and Infectious Disease (NIAID), a division of the National Institutes of Health (NIH).

29 Oct 2009

Avian Influenza News and Research

Former CDC head to lead Merck's vaccine division

Positive interim results from Medicago's H5N1 vaccine Phase I human clinical trial

EPA approves BASF's Aseptrol S10 - Tab for H1N1 sanitization operations

Researchers identify new biological pathway of H1N1 transmission to human population

Computer search algorithms identify FDA-approved drugs that could be the basis for new medicines

Tripep completes phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine

Lethality of H1N1 virus has dropped from its peak of 3.7, shows new data

Inovio Biomedical announces positive test results of its consensus influenza vaccines

DxNA announces successfull evaluation of its GeneSTAT PCR system

Why avian flu virus has not caused a pandemic?

SynCon Chikungunya virus DNA vaccine induces protective neutralizing antibody responses in animal model

Molecular makeup of current H1N1 flu strain strikingly different from previous H1N1 strains

New Web-based application for tracking the H1N1 flu virus across the globe

Scientists find major genetic differences between the pandemic H1N1 strain and seasonal strains

Inovio Biomedical reports financial results for the three and nine months ended September 30, 2009

Pregnant women tolerate the 2009 H1N1 flu vaccine, mount strong immune response

RESPOND program to improve global perspective on emerging diseases

Tufts University receives $185M grant as part of the USAID Emerging Pandemic Threats program

Five-year program aimed at preventing future pandemic diseases awarded to DAI

NIH awards contract to LRRI for anthrax research

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News